ReviewCell proliferation2019
Tumour biomarkers-Tracing the molecular function and clinical implication.
Review in Cell proliferation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Natural Killer Cell-Derived Extracellular Vesicles as a Promising Immunotherapeutic Strategy for Cancer: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Diagnostic value of combination of biomarkers for malignant pleural mesothelioma: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- In-silico investigation reveals microbial metabolic biomarkers and their regulatory roles in hormone sensitive cancers.Journal, genetic engineering & biotechnology · 2025Article
- Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges.MedComm · 2024Review
- A Comprehensive Review of Protein Biomarkers for Invasive Lung Cancer.Current oncology (Toronto, Ont.) · 2024Review
- Feline Chronic Gingivostomatitis Diagnosis and Treatment through Transcriptomic Insights.Pathogens (Basel, Switzerland) · 2024Article
- Exploring the Complexity of Pan-Cancer: Gene Convergences and in silico Analyses.Breast cancer (Dove Medical Press) · 2024Review
- Enrichment of sweat-derived extracellular vesicles of human and bacterial origin for biomarker identification.Nanotheranostics · 2024Article
- Investigating Effects of IR-780 in Animal Models of B16-F10 Melanoma: New Approach in Lung Metastasis.Molecules (Basel, Switzerland) · 2023Article
- A pan-cancer analysis of the expression and prognostic significance of PDRG1.Annals of translational medicine · 2023Article
- Biomarkers or biotargets? Using competition to lure cancer cells into evolutionary traps.Evolution, medicine, and public health · 2023Article
- Exhaled phospholipid transfer protein and hepatocyte growth factor receptor in lung adenocarcinoma.Respiratory research · 2022Article
- Glycopolymer and Poly(β-amino ester)-Based Amphiphilic Block Copolymer as a Drug Carrier.Biomacromolecules · 2022Article
- Specific study of biological tumor cytology: a narrative review.Translational cancer research · 2021Review
- Data mining combined with experiments to validate CEP55 as a prognostic biomarker in colorectal cancer.Immunity, inflammation and disease · 2021Article
- Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.Frontiers in oncology · 2020Review
- Quantification of plasma cell-free DNA levels in dogs with various tumors.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2019Article
- Tumour biomarkers-Tracing the molecular function and clinical implication.Cell proliferation · 2019Review
- The Role Of Circulating Tumor DNA In Therapeutic Resistance.OncoTargets and therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In recent years, with the increase in cancer mortality caused by metastasis, and with the development of individualized and precise medical treatment, early diagnosis with precision becomes the key to decrease the death rate. Since detecting tumour biomarkers in body fluids is the most non-invasive way to identify the status of tumour development, it has been widely investigated for the usage in clinic. These biomarkers include different expression or mutation in microRNAs (miRNAs), circulating tumour DNAs (ctDNAs), proteins, exosomes and circulating tumour cells (CTCs). In the present article, we summarized and discussed some updated research on these biomarkers. We overviewed their biological functions and evaluated their multiple roles in human and small animal clinical treatment, including diagnosis of cancers, classification of cancers, prognostic and predictive values for therapy response, monitors for therapy efficacy, and anti-cancer therapeutics. Biomarkers including different expression or mutation in miRNAs, ctDNAs, proteins, exosomes and CTCs provide more choice for early diagnosis of tumour detection at early stage before metastasis. Combination detection of these tumour biomarkers may provide higher accuracy at the lowest molecule combination number for tumour early detection. Moreover, tumour biomarkers can provide valuable suggestions for clinical anti-cancer treatment and execute monitoring of treatment efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.